Deep Track Capital, LP, together with affiliated entities and David Kroin, filed Amendment No. 2 to Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 6,663,821 shares of X4 Pharmaceuticals, Inc. common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: Deep Track Capital, LP and David Kroin each reported 6,663,821 shares, representing 6.58% of X4 Pharmaceuticals common stock.
  • Pre-Funded Warrants included: The reported holdings include 2,162,137 Pre-Funded Warrants exercisable into common stock, subject to a 9.99% maximum percentage exercise limitation.
  • Master Fund stake: Deep Track Biotechnology Master Fund, Ltd. separately reported 5,737,941 shares beneficially owned, equal to 5.66% of the class.
  • Special Opportunities Fund: Deep Track Special Opportunities Fund, LP reported 925,880 shares, representing 0.91% of the class.
  • Share count basis: The percent-of-class calculations use a denominator of 101,308,880 shares, derived from 99,146,743 common shares outstanding as of July 31, 2026, plus 2,162,137 Pre-Funded Warrants.
  • Shared voting and dispositive power only: All reporting persons reported zero sole voting power and zero sole dispositive power, with all power held on a shared basis.

Deep Track Capital's Reported Position in X4 Pharmaceuticals as of September 30, 2026

According to the filing, Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., Deep Track Special Opportunities Fund, LP, and David Kroin filed this amendment jointly as reporting persons. The event triggering the filing occurred on September 30, 2026. The filing identifies X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) as the issuer, with principal offices at 61 North Beacon Street, 4th Floor, Boston, Massachusetts 02134.

The filing states that Deep Track Capital, LP and David Kroin may be deemed beneficial owners of a combined 4,501,684 shares of common stock and 2,162,137 Pre-Funded Warrants subject to the 9.99% maximum percentage exercise limitation. Deep Track Biotechnology Master Fund, Ltd. is reported as the beneficial owner of 3,575,804 shares of common stock and 2,162,137 Pre-Funded Warrants subject to the same limitation. Deep Track Special Opportunities Fund, LP is reported as the beneficial owner of 925,880 shares of common stock. The filing notes that "the Issuer shall not effect the exercise of any portion of the Pre-Funded Warrants to the extent that after giving effect to such exercise, the holder collectively would beneficially own in excess of 9.99% ... of the number of Common Stock outstanding immediately after giving effect to such exercise."

The filing further states that the securities "were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." David Kroin signed on behalf of all four reporting persons in his capacities as Managing Member of the General Partner of the Investment Adviser for Deep Track Capital, LP and Deep Track Special Opportunities Fund, LP, as Director of Deep Track Biotechnology Master Fund, Ltd., and individually. The filing also identifies Deep Track Capital, LP as the relevant entity for which David Kroin may be considered a control person.

What Was Disclosed

Four affiliated reporting persons jointly filed Amendment No. 2 to Schedule 13G disclosing aggregate beneficial ownership of 6,663,821 shares, or 6.58%, of X4 Pharmaceuticals common stock as of September 30, 2026, including Pre-Funded Warrants subject to a 9.99% exercise cap.